To further evaluate the safety of IL13-BBζ CAR T cells, we developed a fully murine IL13(E12Y)-CAR to better assess off-tumor toxicities in immunocompetent mouse models of GBM, and administered the CAR T cells systemically with and without lymphodepletion. The gene discussed is IL13; the disease is neoplasm.